Broad spectrum antiviral drug inhibits a range of emerging coronaviruses

March 6, 2018, American Society for Microbiology
Credit: CC0 Public Domain

Researchers have long known that RNA viruses called coronaviruses cause the common cold and pneumonia. In the last two decades or so, though, researchers have found that these viruses can jump between animal and human hosts. In recent years, coronaviruses have caused lethal outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) that span multiple continents. To date, no retroviral drug has been approved to treat these infections.

"These viruses are poised to cause outbreaks," says molecular virologist Ralph C. Baric at the University of North Carolina at Chapel Hill, "and most emerging viruses are cyclic in nature." In the case of SARS, the coronavirus caused an outbreak that began in 2003 and was eventually controlled through public health efforts. However, many pre-epidemic forms of the are still around. "We need to have broad-based and potent drugs on a shelf to control future epidemics."

This week in mBio, report on GS-5734, a promising experimental broad spectrum antiviral drug. Previous studies on have shown that the drug inhibits strains of SARS and MERS that infect human airways and the , as well as infection by the Ebola virus. The researchers now report that the drug also inhibits murine hepatitis virus, or MHV, which is closely related to several human coronaviruses that can cause , sometimes as severe as SARS. [image: MERS-CoV within the cytoplasm of an infected cell, credit: CDC]

The researchers tested the drug on mini models of human lungs consisting of , collected from lung transplants. Because those cells express the genes and proteins of the airways that are targeted by coronavirus infections, researchers can use them as a facsimile for host tissue, says Baric.

GS-5734 may be useful in treating a wide range of infections caused by coronaviruses, including contemporary and epidemic strains, as well as those that are poised to jump from an animal host to a human in the future, says Baric. He co-led the study with Mark Denison, a pediatrician and infectious disease expert whose lab at Vanderbilt University in Nashville, Tennessee, focuses on coronaviruses. The researchers also collaborated with Gilead Sciences, a biopharmaceutical company that is developing a phase I clinical trial of the drug for people with MERS in Saudi Arabia.

In another new development reported in the paper, the researchers identified how the virus fights back against the drug, which is crucial information for predicting whether an antiviral might be effective in human hosts. Like many antivirals, GS-5734 is a nucleoside analog, a class of drugs that work by inhibiting the replication of the virus. However, because viruses evolve so rapidly, they quickly develop mutations that confer resistance to these drugs. Researchers at Vanderbilt identified the genetic mutations in the coronaviruses triggered by exposure to GS-5723. Those mutations, however, significantly weakened the virus, which suggests that the drug may be effective enough to outpace viral evolution.

"The location being targeted doesn't seem to have much capacity to evolve and escape the effects of the , says Baric. "Drug resistance was very difficult to achieve."

Epidemics caused by emerging coronaviruses can be devastating. During a SARS epidemic that began in Asia in 2003, for example, more than 8,000 people in 29 countries became infected, and 774 died, according to data from the World Health Organization. The WHO also reports that since September 2012, more than 2,000 people in 27 countries have become infected with MERS, and 750 have died from the infection.

Explore further: Antiviral inhibits epidemic SARS, MERS and animal coronaviruses

Related Stories

Antiviral inhibits epidemic SARS, MERS and animal coronaviruses

June 28, 2017
A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine. The findings ...

What exactly is coronavirus?

January 30, 2015
The conflicts in Syria and Iraq are straining public health systems and public health efforts meant to prevent and detect the spread of infectious diseases. This is generating a "perfect storm" of conditions for outbreaks. ...

New coronavirus inhibitor exhibits antiviral activity by blocking viral hijacking of host

May 29, 2014
Since the SARS epidemic in 2003, coronaviruses have been on the watch list for emerging pathogens, and the ongoing outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) confirmed that they represent a serious ...

Can bats help humans survive the next pandemic?

November 24, 2017
In 2003, severe acute respiratory syndrome (SARS) infected a total of 8,098 people worldwide. First reported in China, it spread rapidly through more than two dozen countries in North America, South America, Europe and Asia.

New SARS-like virus can jump directly from bats to humans, no treatment available

November 10, 2015
Researchers from the University of North Carolina at Chapel Hill have discovered a new bat SARS-like virus that can jump directly from its bat hosts to humans without mutation. However, researchers point out that if the SARS-like ...

New compound inhibits enzyme crucial to MERS and SARS viruses, with a catch

September 8, 2014
Scientists at the University of Illinois, Chicago, have identified a compound that effectively inhibits an enzyme crucial to the viruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome ...

Recommended for you

Small-scale poultry farming could mean big problem in developing countries

December 16, 2018
Small-scale farming in developing countries provides those in rural communities with income and access to protein, but it may have a large impact on antibiotic resistance, according to a new University of Michigan study.

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.